The present disclosure provides a process for preparing cyclophosphamide, intermediate, and the monohydrate thereof.

To provide a material suitable for a nonaqueous electrolyte battery having high-temperature durability. An ionic complex of the present invention is represented by any of the following formulae (1) to (3). For example, in the formula (1), A is a metal ion, a proton, or an onium ion; M is any of groups 13 to 15 elements. R.sup.1 represents a C.sub.1 to C.sub.10 hydrocarbon group which may have a ring, a heteroatom, or a halogen atom, or N(R.sup.2). R.sup.2 at this time represents hydrogen atom, alkali metal atom, a C.sub.1 to C.sub.10 hydrocarbon group which may have a ring, a heteroatom, or a halogen atom. R.sup.2 can also have a branched chain or a ring structure when the number of carbon atoms is 3 or more. Y is carbon atom or sulfur atom. a, o, n, p, q, and r are each predetermined integers. ##STR00001##

To provide a material suitable for a nonaqueous electrolyte battery having high-temperature durability. An ionic complex of the present invention is represented by any of the following formulae (1) to (3). For example, in the formula (1), A is a metal ion, a proton, or an onium ion; M is any of groups 13 to 15 elements. R.sup.1 represents a C.sub.1 to C.sub.10 hydrocarbon group which may have a ring, a heteroatom, or a halogen atom, or N(R.sup.2). R.sup.2 at this time represents hydrogen atom, alkali metal atom, a C.sub.1 to C.sub.10 hydrocarbon group which may have a ring, a heteroatom, or a halogen atom. R.sup.2 can also have a branched chain or a ring structure when the number of carbon atoms is 3 or more. Y is carbon atom or sulfur atom. a, o, n, p, q, and r are each predetermined integers. ##STR00001##

Oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3 and/or 5-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.

Oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3 and/or 5-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.

Provided is a novel imidic acid compound having a divalent anion useful as a pharmaceutical intermediate, an agrochemical intermediate, an acid catalyst, a battery electrolyte or an antistatic agent. The imidic acid compound is a divalent imidic acid compound represented by the following general formula (1) or (2). ##STR00001##
[In formulae (1) and (2), R.sup.1 to R.sup.3 represent a fluorine atom or an organic groups selected from a linear or branched C1-10 alkoxy group, a C2-10 alkenyloxy group, a C2-10 alkynyloxy group, a C3-10 cycloalkoxy group, a C3-10 cycloalkenyloxy group and a C6-10 aryloxy group, and wherein a fluorine atom, an oxygen atom or an unsaturated bond may also be present in the organic group. M.sup.1 and M.sup.2 represent protons, metal cations or onium cations.]

Provided is a novel imidic acid compound having a divalent anion useful as a pharmaceutical intermediate, an agrochemical intermediate, an acid catalyst, a battery electrolyte or an antistatic agent. The imidic acid compound is a divalent imidic acid compound represented by the following general formula (1) or (2). ##STR00001##
[In formulae (1) and (2), R.sup.1 to R.sup.3 represent a fluorine atom or an organic groups selected from a linear or branched C1-10 alkoxy group, a C2-10 alkenyloxy group, a C2-10 alkynyloxy group, a C3-10 cycloalkoxy group, a C3-10 cycloalkenyloxy group and a C6-10 aryloxy group, and wherein a fluorine atom, an oxygen atom or an unsaturated bond may also be present in the organic group. M.sup.1 and M.sup.2 represent protons, metal cations or onium cations.]

A composition comprising an N.sup.2-phosphinylamidine chromium salt complex having Structure FNPACr I:

##STR00001## wherein CrX.sub.p is a chromium salt where X is a monoanion and p is an integer from 2 to 6. A process comprising a) contacting i) ethylene, and ii) a catalyst system comprising an N.sup.2-phosphinylamidine chromium salt complex having Structure FNPACr I:

##STR00002## wherein CrX.sub.p is a chromium salt where X is a monoanion and p is an integer from 2 to 6; and b) forming an oligomer product in a reaction zone.

Dendrimers with monophosphonic or bisphosphonic terminations for the treatment of inflammatory diseases.

Dendrimers with monophosphonic or bisphosphonic terminations for the treatment of inflammatory diseases.